OPNT Opiant Pharmaceuticals Inc.

13.37
+0.56  (+4%)
Previous Close 12.8
Open 12.78
Price To Book 1.73
Market Cap 54,724,623
Shares 4,094,622
Volume 7,756
Short Ratio
Av. Daily Volume 18,789
Stock charts supplied by TradingView

NewsSee all news

  1. Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose

    SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  2. Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

    SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  3. Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  4. Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose

    SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced

  5. Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released February 21, 2019. Endpoints not met.
OPNT001
Bulimia Nervosa
Phase 2 trial to be completed 2H 2020.
OPNT002
Alcohol Use Disorder
FDA approved November 2015.
NARCAN (naloxone HCl) Nasal Spray
Opioid Overdose Reversal
Pivotal PK trial initiation placed on hold pending update from FDA. Unable to verify whether it will be able to initiate the trial in 1Q 2020 as initially guided,
OPNT003
Opioid Overdose

Latest News

  1. Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose

    SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  2. Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

    SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  3. Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

  4. Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose

    SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced

  5. Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today

  6. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current

  7. Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel

    SANTA MONICA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced

  8. Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences

    SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at